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Abstract
Malignant meningiomas (MMs) are aggressive intra-
cranial neoplasms with a 75% 5-year recurrence rate.
Verotoxin 1 (VT1) is an Escherichia coli toxin, which has
recently been shown to have anti–neoplastic action by
targeting the globotriosylceramide (Gb3) glycolipid on
tumor cells and tumor neovasculature. To investigate
the potential use of VT1 as a clinical agent for MM, we
initially tested 16 meningiomas for Gb3 expression. Nine
of 11 MMs (82%), but only one of five benign meningi-
omas (20%), were positive for Gb3. An orthotopic
xenograft model was used to test the efficacy of VT1
treatment for MM. We first demonstrated that Gb3 was
highly expressed by the MM cell line, IOMM-Lee, and
that this cell line was highly sensitive to VT1 treatment in
vitro. A single intratumoral injection of VT1 significantly
improved survival in nude mice harboring intracranial
tumours (P<.0001). Factor-eight immunostaining of
tumours harvested from VT1-treated animals revealed
a marked reduction in the tumour microvascular den-
sity. In addition, the tumors of VT1-treated animals
displayed increased apoptosis by TUNEL analysis and
showed a significant decrease in cell proliferation, as
determined by MIB-5 immunostaining. VT1 treatment of
MM is effective in our orthotopic xenograft model, and
warrants further exploration as a potential treatment for
these highly anaplastic and aggressive neoplasms.
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Introduction
Meningiomas are common tumours of the central nervous
system that have an annual incidence as high as 6/100,000
and account for approximately 20% of all intracranial
neoplasms [1-5]. Pathological studies suggest that these
tumours most often arise form the arachnoidal cap cells of the
inner meninges. Most meningiomas are benign lesions
(World Health Organization, WHO, grade 1), with surgical
extirpation providing a cure for most patients with accessible
tumours [1,4-6]. However, a large number of benign
meningiomas occur in locations such as the skull base
where complete resection is difficult to achieve [4,6]. For
incompletely resected meningiomas, the 10-year recurrence
rate increases dramatically to 78% [4,6]. Even after complete
resection, the recurrence rate for meningiomas is still 20% at
10 years [4-6]. Although rare, meningiomas may harbour
atypical or anaplastic features. Malignant (WHO grade III )
and atypical meningiomas (WHO grade II ) are more prone to
recurrence and aggressive growth than their benign counter-
parts. Patients with malignant meningiomas (MMs) have a
median survival time of less than 2 years after diagnosis
[1,4-7].
Most patients with MMs will receive radiation therapy after
surgery [6,7]. However, radiation therapy alone has proven
ineffective [8 ]. Conventional anti–neoplastic agents have
been administered to small numbers of patients with
meningiomas with minimal benefit [8 ]. Most recently,
hormonal therapy has been attempted, using agents that
block estrogen or progesterone receptors [8,9 ]. However,
trials with tamoxifen, medroxyprogesterone acetate, meges-
trol acetate, and the progesterone receptor antagonist,
RU486 [8,9], have also been disappointing. Clearly, our
current treatment protocols for the management of patients
with malignant and atypical meningiomas are inadequate.
Verotoxin (VT) has been examined recently as a viable,
new agent for the treatment of certain forms of cancer [10-
14]. VTs, also referred to as Shiga- like toxins, are a family of
Escherichia coli–derived subunit protein toxins that are
associated with the pathogenesis of hemolytic uremic
syndrome, hemorrhagic colitis, and microangiopathies [15-
17]. Currently, there are four known members, verotoxin 1
(VT1), VT2, VT2c, and VT2e [15-17]. The VTs consist of a
30-kDa enzymatic A subunit, noncovalently linked to a
pentameric 7-kDa B subunit array, which recognizes and
binds to a specific glycolipid in sensitive cells [15-17]. The
VT receptor is globotriosylceramide (Gb3; gal1–4gal1–
4glc ceramide), which is known to be elevated in several
human neoplasms [10,11,13,14]. Cancer cell lines estab-
lished from such tumours are sensitive to VT in vitro. All the
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VTs have similar biological activities but differ in their
antigenicity, presumably due to their differing B subunits
[15,16]. Despite the involvement of VT in clinical disease,
this property of Gb3 upregulation and VT1 sensitivity found in
human cancers have been exploited to investigate the
possible role of VT as an anti–neoplastic agent. In the case
of astrocytomas, we have previously demonstrated a VT1-
related anti–neoplastic effect using a subcutaneous astro-
cytoma xenotransplant model [11]. In the present study, we
extend this work to show that VT1 is effective against the
Gb3-positive IOMM-Lee MM cell line when grown intra-
cranially in immunocompromised mice.
Materials and Methods
Analysis of GB3 Levels in Human Meningiomas
To detect the VT receptor, Gb3, in surgical specimens of
human meningiomas, 16 frozen tumour specimens were
obtained from the University of Toronto Nervous System
Tissue Bank. Of those, 11 were MMs and five were benign
meningiomas. An immunohistochemical -based method [18]
was performed on 5-m-thick cryostat sections. Briefly,
frozen sections were blocked in 1 mM sodium azide, 10 mM
glucose, and 1 U/ml glucose oxidase (all from Sigma, St.
Louis, MO) to quench endogenous peroxidases. Sections
were subsequently incubated in biotin blocker (kit from
Vector Laboratories, Burlingame, CA) and then in 1% normal
goat serum. In order to mark Gb3, sections were incubated
with 200 ng/ml purified VT1, prepared fresh [10]. After high-
affinity binding of purified VT to Gb3, sections were washed
with phosphate-buffered saline (PBS), incubated with a
mouse monoclonal anti–VT antibody (PH1, dilution 1:1000),
and then treated with a biotinylated goat anti–mouse IgG
antibody (Jackson Immunoresearch Laboratories, West
Grove, PA). Detection was through the ABC (Vector )–
DAB (VectaStain Elite, Vector Laboratories, Burlingame,
CA) system, which was followed by counterstaining with
Meyer’s Hematoxylin, Lillies Modification (Dako, Carpintera,
CA). Tissue sections were dehydrated and then mounted
with paramount (Sigma). In negative controls (one for each
section), incubation with purified VT1 was emitted.
Cell Culture, Gb3 Expression, and VT1 Cytotoxicity of
IOMM-Lee
IOMM-Lee is a MM cell line derived from a 61-year-old
man with repeated recurrent MM of the skull (a kind gift from
Dr. Ian McCutcheon, Department of Neurosurgery, MD
Anderson, Houston, TX) [3 ]. Cells were maintained in
Dulbecco’s modified Eagle’s medium with low glucose and
supplemented with 10% fetal calf serum, 100 U/ml penicillin,
and 100 g/ml streptomycin sulfate. Cells were grown in
monolayer cultures and kept in a humidified environment at
378C and 5% CO2.
To determine the status of Gb3 in IOMM-Lee cells in vitro,
the glycolipid was extracted from cultured cells with 20 vol of
a 2:1 by volume chloroform:methanol solution [10,18]. The
extract was partitioned against water and the lower phase
partitioned again against theoretical upper phase. The lower
phase was dried completely and dissolved in a known
volume of 2:1 chloroform:methanol. The extract and a
standard [consisting of glucosylceramide, lactosylceramide,
Gb3, and globotetraosylceramide (Gb4) ] were separated by
thin- layer chromatography (TLC) [10,18] with chloroform:-
methanol:water; 65:25:4 by volume. The TLC plate was dried
and blocked with 1.5% gelatin in 50 mM TBS at 378C
overnight. The plate was washed with TBS and subsequently
incubated with 0.1 g/ml VT1 and immunodetected using
monoclonal PH1 anti–VT1 antibody for 1 hour and then goat
anti–mouse antibody conjugated to peroxidase (Sigma).
Alternatively, the same preparation was sprayed with orcinol
for straight detection of Gb3.
To evaluate the in vitro efficacy of VT1 on IOMM-Lee
cells, a VT1 cell viability assay was performed [10]. Cells
grown to confluence were trypsinized and seeded in 96-well
dishes at a density of 5000 cells /well for 24 hours at 378C
prior to treatment with VT1. Ten- fold serial dilutions of VT1
or sodium azide as a positive control were prepared and
added to cells. Each dilution was tested in triplicate.
Following 1- , 2- , 3- , and 5-day incubations at 378C, the
cells were fixed in 2% formaldehyde in PBS, stained with
crystal violet, and then added to a 10% acetic acid solution to
solubilize the crystal violet. The percentage of live cells was
calculated by absorbance at 590 nm using a microtiter plate
reader (Dynatech Laboratories, Chantilly, VA). The apop-
totic effects of VT1 on IOMM-Lee cells in culture were also
tested. Briefly, approximately 5000 IOMM-Lee cells were
plated on Teflon-masked 10-well glass slides (Creative
Scientific Methods, Phoenix, AZ) coated with poly L- lysine
(Sigma). Cells were then incubated with varying concen-
trations of VT1 at 378C. After several time points, cells were
washed and then incubated for 30 minutes at room temper-
ature with 20 l /ml annexin V Alexa 568 (Roche Biochem-
icals, Mannheim, Germany) and 0.5 g/ml DAPI ( in 10 mM
HEPES, pH 7.4, 140 mM NaCl, and 5 mM CaCl2, all from
Sigma) for the detection of phosphatidylserine on the outer
leaflet of apoptotic cells and cell nuclei, respectively. All
doses and time points were done in duplicate. Cells were
analyzed by fluorescence microscopy.
Orthotopic Intracranial MM Model
A total of 75 six- to eight -week-old female athymic nude
mice (CD1, nu/nu; Charles River Breeding Laboratory,
Wilmington, MA) weighing 22±3 g were used for tumour
inoculation. All animals were housed in a closed colony in
the animal care facility at The Hospital for Sick Children. The
protocol followed the guidelines and regulations of the
Animal Care Committee. Animals were anesthesized intra-
peritoneally with a 1:1 combination of Hypnorm (composi-
tion: 0.315 mg fentanyl citrate/ml, 10 mg fluanisone/ml,
diluted 1:4 in sterile water; Jansen Pharmaceutica, Beerse,
Belgium) and Midazolam (5 mg/ml, diluted 1:6.6 in sterile
water; Roche Diagnostics, Mississauga, Canada) at a dose
of 0.1 ml /10 g.
Mice were stabilized in a stereotactic head frame (ASI
instrument, small animal stereotactic frame). The head was
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prepped with betadine iodine and a subperostial injection of
Lidocaine (Abbott Laboratories, Abbott Park, IL) was given.
A linear skin incision was subsequently made at the midline,
skin was retracted, and the periosteum elevated. A burr hole
(Dremel Drill, Racine, WI) was drilled in the anterior right
frontal region of the cranium, lateral to the midline and
anterior to the bregma suture. A nylon guide screw (Depart-
ment of Biomedical Engineering, The Hospital for Sick
Children, Toronto, Canada) [19] was placed securely in
the burr hole and the incision was closed with interrupted
Dexon 5-0 sutures. Animals were given a subcutaneous
injection of saline and kept warm until recovery.
One week following placement of the guide screw, the
animals were reanesthesized and their wounds reopened.
Confluent cultures of IOMM-Lee were harvested using
0.05% trypsin for 2 minutes at 378C. After neutralization of
trypsin with media, cells were pelleted by centrifugation and
then washed with sterile PBS. The cell pellet was resus-
pended in sterile PBS. Approximately 1106 cells (3 l vol )
were drawn with the Hamilton syringe and were injected
slowly to a depth of 5 mm through the guide screw. The skin
was closed and the animals were allowed to recover as
above.
VT1 Treatment of Mice Harboring Intracranial Meningiomas
and Survival Analysis
Six days following tumor implantation, animals were
weighed and randomized to receive one of three treatments:
1) VT1, 2) heat- inactivated VT (HI-VT), or 3) PBS — the
latter two serving as controls. Active VT1 was prepared for
administration as described [10], or it was inactivated by
Table 1. Semiquantitative Analysis of Gb3 Expression in HumanMeningiomas
(n=16 ).
Strength of
Gb3 Staining
Number of MMs
Staining Positive
Number of
Benign Meningiomas
Staining Positive
+ + + + 2
+ + + 2
+ + 2
+ 3 1
0 2 4
Figure 1. Photomicrograph (original magnification, 200 ) illustrating immunohistochemical staining of Gb3 in human meningiomas. (A ) A malignant meningioma
representing very strong ( + + + + ) Gb3 immunoreactivity ( brown ) where staining is both vascular and extravascular. (B ) A MM semiquantitated as strong staining
( + + + ) primarily due to the predominantly vascular localization of Gb3. (C ) A benign meningioma showing no evidence of Gb3 positivity. (D ) A MM (same as in B )
showing no Gb3 immunoreactivity when VT1 is omitted.
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heating at 808C or higher for 1 hour. VT1 was prepared fresh
each time in sterile PBS to a concentration that would
administer 2 g/kg VT1 or HI-VT toxin in a single dose. Mice
were once again anesthesized and their wounds reopened.
The Hamilton syringe was used to inject VT1 or controls to
precisely determine the same depth of the previously
implanted tumor cells through the guide screw in a 2-l
injection volume. After the wounds were closed, the animals
were monitored daily for neurological changes and weighed
every other day. Survival was measured in days post tumour
cell inoculation. Animals were sacrificed by placing them in a
mixed CO2 and O2 gas chamber. Immediately after sacrifice,
the brains of animals were removed and embedded in OCT
(Tissue Tek) embedding medium on dry ice and stored at
808C until further processing.
Immunohistochemical Analysis of Proliferation,
Microvascular Density (MVD), and Apoptosis
Coronal, 5-m cryostat sections were fixed in acetone
and immunohistochemical procedures were performed for
immunodetection of MIB-5 and Factor VIII. The procedure
was carried out on the NEXES autoimmunostainer (Ventana
Medical Systems, Tuscon, AZ) with either a mouse mono-
clonal anti–MIB-5 antibody (dilution: 1:20; Dako), or a
polyclonal anti–Factor VIII antibody (dilution: 1:400; Dako).
MIB-5 reactivity was visualized using a modification of the
MOM ABC (Vector Laboratories; cat no. Pk-2200)–DAB
system. For Factor VIII, visualization of positive staining
was through the ABC system employing the Ventana DAB
detection system.
Apoptosis was examined by the TUNEL ( terminal
deoxynucleotidyl transferase-mediated dUTP biotin end
labeling) method using the In Situ Cell Death Detection
POD kit (Roche Diagnostics; cat no. 1684817) with some
modifications. Briefly, sections were fixed in 4% paraformal-
dehyde and washed in PBS. Endogenous peroxidases
were blocked in 0.3% hydrogen peroxide in methanol. The
TUNEL reaction mixture was added to the tissue and
incubated at 378C for 60 minutes. After washing in PBS,
sections were treated with a protein block and incubated
with the Converter POD (anti– fluorescein antibody con-
jugated to horseradish peroxidase) at 378C for 30 minutes.
Detection of incorporation of dUTP was achieved by treating
the sections with DAB in hydrogen peroxide (Sigma). All
sections were counterstained with haematoxylin, dehy-
drated, and mounted.
Semiquantitative and Statistical Analyses
The apoptotic index of IOMM-Lee cells in culture was
obtained by averaging the percentage of annexin V–
positive cells in five high-powered fields (HPFs) (400
Figure 2. Detection of the VT receptor glycolipid, Gb3, in IOMM-Lee cell line.
A TLC separation of the glycolipid visualized by orcinol ( left ). The right panel
is the same preparation assayed by VT1 overlay. As seen from the TLC plates,
Gb3 is expressed ( left ) and binds to VT1 ( right ) in IOMM-Lee.
Figure 3. VT1 sensitivity of IOMM-Lee cells. (A ) Increasing concentration
of toxin by 10 - fold dilutions leads to a decrease in the number of viable
cells (CD50 of 0.01 g /ml ) and this dose response is sustained over the
course of 1, 2, 3, and 5 days after initial treatment with VT1 (n=3 for each
point on the graph ). (B ) The percentage of annexin V–positive cells, an
indicator of cell death, increases with higher concentrations of VT1 (0.001,
0.1, and 10 g /ml ). Each bar graph represents average percentages of five
HPFs taken from two samples.
Figure 4. Survival analysis of mice treated with VT1, HI -VT, or PBS. Kaplan -
Meier curve demonstrates that VT1 - treated mice survive significantly longer,
up to 49 days post tumour cell inoculation, than either of the control groups
which only had mice live up to a maximum of 19 days (P < .0001, log - rank test
for survival ).
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magnification). Cells negative for annexin V were identified
by DAPI. For immunohistochemical quantitation, entire
tissue sections were analyzed for the strength of positive
Gb3 staining obtained and scored on a scale ranging from
‘‘+ ’’ (very little staining) to ‘‘+ + +’’ (very strong staining).
Negative control slides were also scored. The mouse brain
sections were analyzed by Scion Image Beta 4.02 (down-
loaded from http: / /www.scioncorp.com, NIH image). First,
five HPFs (400 magnification) were acquired from
representative and random sites in the tumour using a
digital CCD CoolSnap camera (Photometrics, Trenton, NJ)
mounted on a DMLB Leica light microscope (Photomet-
rics). The MIB-5 and TUNEL labeling indices were obtained
by averaging the percentage of positively stained nuclei in
five HPFs [20]. MVD was calculated by averaging the
number of Factor VIII–positive vessels per five HPFs [21].
In order to determine statistical significance (P<.05)
between groups, multiple comparisons of the data set were
performed using the analysis of variance (ANOVA) stat-
istical test. Survival data of animals were plotted on a
Kaplan-Meier curve and the log-rank (Manley-Cox)
statistical test for survival was performed.
Results
VT Receptor Expression in Human Meningiomas
The VT receptor, Gb3, was elevated in MMs when
compared to benign meningiomas (Table 1). Of 11 MMs
examined, nine were positive for Gb3; interestingly, the
degree of Gb3 immunoreactivity was variable (Table 1,
Figure 1 ). Four of nine Gb3-positive tumours demonstrated
strong expression of the glycolipid. In all positive samples,
Gb3 was primarily localized to the microvasculature with
immunoreactivity often demarcating the presence of many
vessels (Figure 1;A and B ). In two tumors with strong
staining, immunoreactivity was found not only within the
vasculature, but also within tumour cells (Figure 1A ). Only
one of five benign meningiomas demonstrated any Gb3
positivity, and this was extremely faint (Figure 1C ). In tissue
sections serving as control (VT1 emitted) no Gb3 immunor-
eactivity was detected (Figure 1D ).
IOMM-Lee Cells Express Gb3 and are Sensitive to VT1
The Gb3 status of IOMM-Lee cells was determined by
TLC of the glycolipid extract and was followed by orcinol
Figure 5. Immunohistochemical analysis of VT1 -associated anti –neoplastic effects in IOMM-Lee tumours. Photomicrographs ( original magnification, 400 )
illustrates the marked reduction in MVD (Factor VIII ) and the proliferation index (MIB -5 ) in VT1 - treated animals when compared to control groups. Additionally, this
figure depicts the remarkable increase in the percentage of cells undergoing apoptosis (TUNEL ) in animals treated with VT1. The brown staining indicates
immunoreactivity.
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spray or a VT1 overlay to detect Gb3 binding to VT.
Consistent with the demonstration of Gb3 within IOMM-
Lee cells (Figure 2 ), the cell viability assay demonstrated
that IOMM-Lee was sensitive to VT1 in a dose-dependent
manner (Figure 3 ). However, our results suggest that the
effects of VT1-mediated toxicity are a sustained effect over
the time period studied (Figure 3A ). The CD50 of cells at day
3 post VT1 treatment was 0.01 g/ml. The other time points
were within 1log difference of the CD50 at this time point. The
cell growth seen at day 5 post VT1 treatment can be
attributed to cells beginning to repopulate the wells. Treat-
ment of cells with 10 mM sodium azide resulted in 100% kill
of cells (data not shown). Similarly, the results of our annexin
V study suggest that cells were inducing apoptosis in a
dose-dependent fashion with no significant evidence of a
time-dependent response (Figure 3B ).
Survival Studies
Four of 75 animals studied died immediately postoper-
atively and were not included in survival studies. There were
a total of 28 animals treated with VT1, but one animal was
sacrificed prematurely due to severe conjunctivitis and was
not included in any further analysis. Twenty- five and 15
animals were used in the HI-VT and PBS groups,
respectively, and three animals were included in a sham
surgery arm in which they received the anesthetic, a scalp
incision, and burr hole but received neither cells nor
treatment.
A single intratumoral VT1 injection was sufficient to
increase the survival of nude mice harboring IOMM-Lee
tumours intracerebrally by a significant factor (P<.0001,
log-rank test for survival; Figure 4 ). A total of 27 nude mice
received a single dose (2 g/kg) of active VT1. The median
survival for VT1- treated animals was 17 days and the
survival ranged from 9 to 49 days. For control, a total of
25 animals received a single injection of either HI -VT1
(2 g/kg) or 15 animals received a single injection of PBS.
The median survival for animals treated with HI-VT or PBS
was 13 days for both groups, and in these groups, survival
ranged from 11 to 19 days. The three animals that underwent
sham surgery (no cell inoculation, or treatment) outlived all
experimental mice and showed no evidence of disease
symptoms (data not shown). Their brains were harvested
and used as normal brain control for later immunohisto-
chemical studies. Tumor take was 100% as was evident
from histological assessment of mouse brains. A critical
endpoint criterion in the survival study involved monitoring
weight loss and ensuring that animals were sacrificed within
a narrow margin of a 20% loss in body weight. All three
treatment groups were sacrificed within this parameter. The
average weight of VT1- treated animals at sacrifice was
17.3 g (18.4% loss of body weight ); for HI -VT–treated
animals, the average weight was 21.2 g (19.1% loss of
body weight ); and for PBS-treated animals, the average
weight was 21.4 g (22.7% loss of body weight ). The
differences in weight between the groups were not statisti-
cally significant.
Effects of VT1 on IOMM-Lee Proliferative Index,
Vascularity, and Apoptosis
The MIB-5 labeling index of VT1- treated animals was
20±0.029%, a significant reduction in the percentage of
proliferating cells when compared to control - treated animals
[HI-VT, 36±0.05% (P<.0043) and PBS, 31±0.007%
(P<.0248) ] (Figures 5 and 6 ). No significant different was
found between HI-VT and PBS (P<.6543).
To assess the anti–angiogenic effects of VT1, an anti–
Factor VIII antibody was used to stain the microvasculature
of IOMM-Lee–derived tumours. The number of Factor VIII–
positive blood vessels was compared among the three
experimental groups. There was a marked reduction in the
MVD of VT1- treated animals when compared to HI-VT–
and PBS-treated animals (Figures 5 and 7 ). This is best
exemplified by MVD raw counts of 5±0.42 for VT1- treated
animals and 11.9±0.79 or 11.6±1.35 for HI -VT and PBS
groups, respectively. In addition, blood vessels associated
with either of the control groups appeared larger and more
robust than the blood vessels of the VT1- treated animals
(Figure 5 ). ANOVA demonstrated statistical significance
between the VT1 and HI-VT groups (P<.0001) and
between the VT1- and PBS-treated groups (P<.0001).
There was no significant difference between the PBS- and
HI-VT–treated groups (P<.693).
Figure 6. Anti –proliferative effects of VT1 on IOMM-Lee–derived tumours.
Graph illustrates a reduction in the percentage of cells stained with the
proliferation marker, MIB -5, in VT1 - treated animals ( 20±0.029%). Com-
pared to HI -VT (36±0.05%, P< .0043 ) and PBS (31±0.007%, P< .0248 ), no
significant different was found between HI -VT and PBS (P< .6543 ).
Figure 7. Angiogenesis in IOMM-Lee tumours of treated animals. The graph
depicts a decrease in the MVD of animals treated with VT1 (5±0.42 ). This is
compared to HI -VT - treated ( 11.9± 0.79, P< .0001 ) and PBS - treated
( 11.6±1.35, P< .0001 ) animals. These values were obtained by averaging
the number of Factor VIII –stained vessels in five HPFs. There was no
significant difference between the PBS - and HI - VT– treated groups
(P< .693 ).
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The level of apoptosis within the tumour xenograft
following VT1 injection was determined by TUNEL staining.
In animals treated with VT1, 51±0.04% of cells was
undergoing apoptosis, which is remarkably higher than the
apoptotic indices of either HI -VT–treated (2.6±0.009%,
P<.0001) or PBS-treated (4.3±0.012%, P<.0001) animals
(Figures 5 and 8 ). There was no statistical significance
between the levels of apoptosis in HI-VT– and PBS-treated
animals (P<.6254).
Discussion
In this study, we have shown that a single intratumoral
injection of VT1 was sufficient to significantly improve
survival in nude mice bearing intracranial MM. These results
are particularly promising when one considers the upregu-
lation of Gb3 observed in 9/11 human cases of MM. On the
other hand, the benign meningiomas examined here were
virtually all negative for expression of the glycolipid. As such,
we would predict that VT1 may not be an effective agent for
this histologic subtype of meningioma. Based on the
percentage of VT1- treated animals that outlived the median
survival of animals in control groups, approximately 70% of
animals treated with VT1 has shown a response to treatment.
VT1 is a type II ribosome- inactivating protein produced by
pathogenic strains of E. coli and only targets cells that
express the glycolipid, Gb3, otherwise known as CD77 [16].
Based on the observations that Gb3 is upregulated in many
human neoplasias including cancers of breast, ovarian,
testicular, hematologic, and astrocytic origin, several studies
to date have exploited the notion that VT may be a viable
approach to cancer treatment [10-14,22,23]. Additionally,
VT1 treatment of mice bearing Gb3-positive tumours was
found to prevent metastasis [12] and reduce tumour burden
in mice harboring subcutaneous astrocytic tumours [11].
Furthermore, drug-resistant ovarian tumours were also
found to express higher levels of Gb3 than the primary tumor
[22]. Interestingly, multiple drug-resistant variants of such
cell lines were found to be hypersensitive to VT1 and cell
transfection with MDR1 has been found to dramatically
increase Gb3 and susceptibility to VT [11]. This suggests a
particularly attractive potential that VT could be used as a
therapeutic against drug-resistant tumours where prior
chemotherapy had failed, as is the case for many brain
tumours including MMs [8] and astrocytomas [11].
Expectedly, not all animals in our study treated with VT1
responded to treatment. One explanation could simply be
related to the intrinsic biological variation among mice.
Additionally, whereas a significant effect on survival was
achieved with only a minimal dose of VT1 (2 g/kg; LD50 is
40 g/kg) [11], a better response to treatment is likely
attainable if the administration of VT1 is further optimized,
namely, by increasing the dose or possibly by giving multiple
injections. An intriguing observation is the relative insensi-
tivity of human cerebral capillary endothelial cells to VT [10].
Thus, increasing the dose of VT1 administered is likely not to
be toxic to the normal brain vasculature. Capillary endothelial
cells derived from kidney and the large bowel appear to be
the primary targets of VT-associated injury in hemolytic
uremic syndrome and hemorrhagic colitis [14-16]. This has
not been a concern with direct intracranial, intratumoral
administration of VT1. Fortunately, we have performed
previous murine toxicology studies in our laboratory, which
have indicated that mice are able to tolerate 10 times the
LD50 dose of VT1 when given intracerebrally without
demonstrating any symptoms or signs affecting either the
renal or gastrointestinal systems (unpublished data).
Gb3 levels in endothelial cell cultures, and thereby their
sensitivity to VT, have been shown to be modulated in the
presence of various cytokines [14,24]. It is possible that
cytokines secreted by the tumour cells in meningiomas
[25,26] act in a paracrine fashion to upregulate Gb3
expression in tumour-derived endothelial cells, in turn
rendering them susceptible to VT1. This hypothesis is
consistent with our data, which have clearly demonstrated
increased Gb3 expression in the vasculature of human MMs.
This is further supported by the fact that VT1 led to an anti–
angiogenic effect, as seen by the reduction in the MVD of
IOMM-Lee tumours. Meningiomas are known to be highly
vascularized tumours and known to induce angiogenesis by
paracrine mechanisms involving one or more molecules like
vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) [27,28]. Therefore, mole-
cules such as VT1, which are known to inhibit angiogenesis,
may prove to be clinically efficacious.
Homeostatic control of cell number is the result of a
dynamic balance between cell proliferation and cell death. It
is evident from our study that VT1 targets both components
of this equation by inhibiting cell proliferation through the
inhibition of protein synthesis and increasing cell death by
inducing apoptosis. It has been shown that the B subunit is
capable of inducing apoptosis independent of the enzymatic
actions of the A subunit [29]. Therefore, in addition to cell
death by the inhibition of protein synthesis, VT holotoxin is
capable of inducing apoptosis. For example, it has been
shown that Gb3-positive Burkitt lymphoma cells and
germinal B lymphocytes are highly susceptible to apoptosis
by the VT1-B subunit [29]. Apoptosis is an important cellular
Figure 8. Treatment with VT1 leads to a proapoptotic effect. TUNEL staining
of IOMM-Lee tumours treated with VT1 (51±0.04%) shows a remarkable
increase in the number of cells undergoing apoptosis. This is contrasted with
the apoptotic indices of HI -VT– treated (2.6±0.009%, P< .0001 ) and PBS -
treated ( 4.3±0.012%, P< .0001 ) animals. There was no statistical signifi-
cance between the levels of apoptosis in HI -VT– and PBS - treated animals
(P< .6254 ).
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process within multicellular organisms and is clearly a target
in the design of anti–neoplastic regimes [11].
The use of VT in an in vivo therapeutic setting appears
challenging at the present time because of its association
with hemolytic uremic syndrome and hemorrhagic colitis.
However, we believe that a therapeutic window of oppor-
tunity exists for VT1 in cancer therapy. For example,
hemolytic uremic syndrome and hemorrhagic colitis are
diseases at the extremes of age, under age 3 and over age
70, respectively. This indicates that the general adult
population is resistant to VT- induced pathology [15]. In
addition, topical application or local deposition ( intratumoral )
of the toxin into a confined body compartment, such as in the
current study, represents possible options. The brain is
especially privileged to local treatment because the diffusion
of macromolecules to and from the brain is especially limited
by the blood–brain barrier [13].
Our current studies have described the Gb3 receptor
status and VT1 sensitivity in the MM cell line, IOMM-Lee,
and has shown the potency of VT1 treatment in vivo by
employing an orthotopic mouse model of IOMM-Lee.
Clearly, a plethora of potent anti–neoplastic effects on
intracerebral IOMM-Lee tumours was evident. These anti–
neoplastic mechanisms effectively increased the survival of
nude mice with only a single injection of the toxin intra-
tumorally. Taken together, it is not unreasonable to believe
that MMs and other brain tumours alike, which express Gb3,
could be the target for VT1 therapy.
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